A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma.

COVID-19 ELISA antithrombin coagulation factor IXa human monoclonal antibody protease zymogen

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 15 09 2023
revised: 21 12 2023
accepted: 18 01 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Factor (F)IXa activity has been detected in human plasma and may impact thrombotic risk. Current FIXa activity assays are complex and cumbersome. To develop a reproducible enzyme-linked immunosorbent assay (ELISA) using a novel monoclonal antibody that detects total FIXa in human plasma. A monoclonal antibody was raised against the new N-terminus exposed upon activation of FIX to FIXa by cleavage after R226. This antibody is specific for FIXa protease and does not recognize FIX zymogen or FIXα. The antibody was used to develop a FIXa-specific ELISA capable of quantifying total FIXa (free FIXa and FIXa-antithrombin complex) in human plasma. Total FIXa quantified using the ELISA was compared to that of FIXa-antithrombin quantified using modifications of a previously described ELISA. The FIXa-specific ELISA was reproducible and quantified total FIXa in human plasma. Total FIXa levels correlated with FIXa-antithrombin levels. A monoclonal antibody was developed that specifically detects human FIXa protease. A FIXa-specific ELISA using the new antibody is capable of reproducibly measuring total FIXa in human plasma (both free FIXa and FIXa-antithrombin). This assay should facilitate the evaluation of total FIXa levels in a variety of clinical circumstances.

Sections du résumé

Background UNASSIGNED
Factor (F)IXa activity has been detected in human plasma and may impact thrombotic risk. Current FIXa activity assays are complex and cumbersome.
Objectives UNASSIGNED
To develop a reproducible enzyme-linked immunosorbent assay (ELISA) using a novel monoclonal antibody that detects total FIXa in human plasma.
Methods UNASSIGNED
A monoclonal antibody was raised against the new N-terminus exposed upon activation of FIX to FIXa by cleavage after R226. This antibody is specific for FIXa protease and does not recognize FIX zymogen or FIXα. The antibody was used to develop a FIXa-specific ELISA capable of quantifying total FIXa (free FIXa and FIXa-antithrombin complex) in human plasma. Total FIXa quantified using the ELISA was compared to that of FIXa-antithrombin quantified using modifications of a previously described ELISA.
Results UNASSIGNED
The FIXa-specific ELISA was reproducible and quantified total FIXa in human plasma. Total FIXa levels correlated with FIXa-antithrombin levels.
Conclusion UNASSIGNED
A monoclonal antibody was developed that specifically detects human FIXa protease. A FIXa-specific ELISA using the new antibody is capable of reproducibly measuring total FIXa in human plasma (both free FIXa and FIXa-antithrombin). This assay should facilitate the evaluation of total FIXa levels in a variety of clinical circumstances.

Identifiants

pubmed: 38433974
doi: 10.1016/j.rpth.2024.102338
pii: S2475-0379(24)00026-8
pmc: PMC10907220
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102338

Informations de copyright

© 2024 The Author(s).

Auteurs

Tina M Misenheimer (TM)

Morgridge Institute for Research, Madison, Wisconsin, USA.

Michael R Lasarev (MR)

Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.

Kraig T Kumfer (KT)

Morgridge Institute for Research, Madison, Wisconsin, USA.
Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.

John P Sheehan (JP)

Department of Medicine/Hematology-Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
University of Wisconsin-Madison Carbone Cancer Center, Madison, Wisconsin, USA.

Bradford S Schwartz (BS)

Morgridge Institute for Research, Madison, Wisconsin, USA.
Departments of Medicine/Hematology-Oncology, and Biomolecular Chemistry, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.

Classifications MeSH